Co-Diagnostics Adjourns Annual Meeting, Sets New Date
I'm LongbridgeAI, I can summarize articles.Co-Diagnostics (CODX) adjourned its Annual Meeting of Stockholders on September 3, 2026, due to a lack of quorum. The meeting has been rescheduled for September 24, 2026, in Salt Lake City. Valid proxies from the original date remain effective for the reconvened session unless revoked. This procedural setback preserves shareholder voting rights while maintaining continuity in proxy handling.
Co-Diagnostics ( (CODX) ) just unveiled an announcement.
Co-Diagnostics, Inc. held its previously announced Annual Meeting of Stockholders on September 3, 2026, but the meeting failed to reach a quorum and therefore could not conduct any formal business. Under the company’s bylaws, the chairperson adjourned the meeting and rescheduled it for September 24, 2026, at the company’s Salt Lake City offices, with shareholders able to participate and vote as outlined in the definitive proxy statement filed on July 21, 2026.
The company confirmed that all valid proxies submitted ahead of the original meeting will remain effective for the reconvened session unless they are properly changed or revoked before voting begins. The adjournment highlights a procedural setback in the company’s annual governance process, but preserves shareholder voting rights and maintains continuity in how proxies and participation will be handled at the rescheduled meeting.
The most recent analyst rating on (CODX) stock is a Buy
with a $4.00 price target.
To see the full list of analyst forecasts on Co-Diagnostics stock,
see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
The score is driven primarily by very weak financial performance (collapsed revenue, large ongoing losses, and sustained cash burn with a reduced equity base). Technicals also reflect a pronounced downtrend. Regulatory/operational milestones and expense reductions are constructive, and the new financing helps near-term liquidity, but very low revenue and tight cash levels keep risk elevated.
To see Spark’s full report on CODX stock,
click here.
More about Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company that develops and commercializes polymerase chain reaction (PCR) tests and related technologies for infectious diseases and other health conditions, with its operations and corporate offices based in Salt Lake City, Utah.
Average Trading Volume: 458,153
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.28M
Find detailed analytics on CODX stock on TipRanks’ Stock Analysis page.